PYXS is trading at $2.43 (up 9%) on continued short-term momentum, extending the stock's recent rebound despite a lack of fresh company-specific catalysts.
- No new earnings, FDA decisions, or analyst updates were identified for June 26, 2026, suggesting the move is driven by technical buying rather than news headlines.
- The stock is significantly outperforming broader market indices, which are trading slightly lower today, indicating strong stock-specific interest.